Table 3 First-Line and Second-Line Treatment Regimens
Regimen | Patients, n (%) | |
|---|---|---|
1 L therapy (n = 1003) | 2 L therapy (n = 287) | |
Chemotherapy | ||
 Carboplatin-based doublet or triplet therapya | 499 (49.8) | 57 (19.9) |
 Carboplatin | 3 (0.3) | 0 |
 Cisplatin-based doublet or triplet therapya | 172 (17.1) | 7 (2.4) |
 Docetaxel | 5 (0.5) | 17 (5.9) |
 Docetaxel + nintedanib | 4 (0.4) | 16 (5.6) |
 Gemcitabine | 3 (0.3) | 1 (0.3) |
 Nintedanib | 0 | 1 (0.3) |
 Paclitaxel | 0 | 4 (1.4) |
 Pemetrexed | 9 (0.9) | 0 |
 Vinorelbine | 3 (0.3) | 1 (0.3) |
Immuno-oncology therapy | ||
 Atezolizumab | 0 | 32 (11.1) |
 Nivolumab | 5 (0.5) | 20 (7.0) |
 Pembrolizumab | 174 (17.3) | 96 (33.4) |
Targeted therapyb | ||
 Afatinib | 67 (6.7) | 5 (1.7) |
 Alectinib | 2 (0.2) | 2 (0.7) |
 Ceritinib | 6 (0.6) | 3 (1.0) |
 Crizotinib | 11 (1.1) | 4 (1.4) |
 Erlotinib | 12 (1.2) | 5 (1.7) |
 Gefitinib | 24 (2.4) | 3 (1.0) |
 Osimertinib | 4 (0.4) | 13 (4.5) |